Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for aTyr Pharma, Inc. (ATYR : NSDQ)

• Company Description    aTyr Pharma, Inc. is a bio-therapeutics company. The Company is involved in the discovery and development of medicines for severe, rare diseases of physiological modulators. aTyr Pharma, Inc. is a based in SAN DIEGO, United States. Number of Employees: 59

• Price / Volume Information    Yesterday's Closing Price: $5.26 Daily Weekly Monthly 20 Day Moving Average: 4,069,044 shares Shares Outstanding: 97.99 (millions) Market Capitalization: $515.41 (millions) Beta: 1.01 52 Week High: $7.29 52 Week Low: $1.67 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 5.41% 3.51% 12 Week 1.74% -7.63% Year To Date 45.30% 29.74%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 10240 Sorrento Valley Road Suite 300 - SAN DIEGO,CA 92121 USA ph: 858-731-8389 fax: 858-731-8394 investorrelations@atyrpharma.com http://www.atyrpharma.com

• General Corporate Information    Officers Sanjay S. Shukla - President; Chief Executive Officer and Director Timothy P. Coughlin - Chairman of the Board Jill M. Broadfoot - Chief Financial Officer Eric Benevich - Director John K. Clarke - Director Peer Information aTyr Pharma, Inc. (CORR.) aTyr Pharma, Inc. (RSPI) aTyr Pharma, Inc. (CGXP) aTyr Pharma, Inc. (BGEN) aTyr Pharma, Inc. (GTBP) aTyr Pharma, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 002120202 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/06/25 Share - Related Items Shares Outstanding: 97.99 Most Recent Split Date: 7.00 (0.07:1) Beta: 1.01 Market Capitalization: $515.41 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.16 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.70 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/06/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 6.27 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 4.35% vs. Previous Quarter: -29.41% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - -93.69 03/31/25 - -87.09 12/31/24 - -85.17 ROA 06/30/25 - -68.83 03/31/25 - -64.77 12/31/24 - -62.82 Current Ratio 06/30/25 - 5.63 03/31/25 - 7.79 12/31/24 - 5.48 Quick Ratio 06/30/25 - 5.63 03/31/25 - 7.79 12/31/24 - 5.48 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - -27,243.40 Book Value 06/30/25 - 0.84 03/31/25 - 0.84 12/31/24 - 0.83 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - 0.01 03/31/25 - 0.01 12/31/24 - 0.01 Debt-to-Capital 06/30/25 - 0.80 03/31/25 - 0.99 12/31/24 - 1.25

Powered by Zacks Investment Research ©